Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with shamat one year in patients receiving complete ...
Fractyl reported clinical trial results demonstrating that patients maintained up to 84% of GLP-1-induced weight loss with ...
Zacks Investment Research on MSN
Fractyl Health stock up on encouraging one-year Revita study results
Fractyl Health, Inc. GUTS reported positive one-year results from the randomized, sham-controlled Midpoint Cohort of its ...
Fractyl Health (GUTS) stock jumps as the Revita procedure reduced weight regain by roughly 40% following GLP-1 ...
Fractyl Health Inc. GUTS reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single ...
Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, a commercial stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D), ...
Fractyl Health is under fresh scrutiny after analysts reset its fair value estimate from US$7.44 to US$5.03 per share, a ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and ...
(Reuters) - Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million. After a two-year lull, initial ...
Fractyl Health, Inc. (NASDAQ:GUTS) shares are trading lower. The company announced new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform. What To Know: The data, shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results